Navigation Links
Neptune Products to be commercialized by BAYER HealthCare
Date:6/4/2009

LAVAL, QC, June 4 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced that it has signed an agreement with Bayer Healthcare, LLC for the commercialization of Neptune proprietary products in the United States.

"The signing of this agreement with a partner of the caliber of Bayer supports Neptune's business and scientific choice to pursue the more demanding and challenging clinical development path of assessing safety and effectiveness of its products. As planned, it has been strategic to invest the time and resources into building a complete portfolio of scientific data, intellectual property and regulatory approvals which ultimately allowed the Company to attract the best partner," stated Dr. Tina Sampalis, Chief Scientific Officer of Neptune.

"Neptune's approach to commercialization consists of rapidly penetrating the market to generate short-term revenue and growth by partnering with the right marketer that can create broad consumer awareness leveraged by our substantial scientific data and that can create large market share for Neptune. Bayer is among the world's largest marketers of healthcare products," she added.

"Through the capabilities, reputation and commitment of its partners favoring growth, Neptune leverages and maximizes value by opening doors for future product and business development opportunties developed by Neptune and its pharmaceutical subsidiaries," stated Mr. Henri Harland, Chief Executive Officer and President of Neptune. "The parallel stepwise approach of exploring other future products and project opportunities directed towards pharmaceutical driven applications is part of the plan," he added.

"Under Neptune's strategic vision, which has been pursued since the beginning of its operations, the Company has anticipated to penetrate world nutraceutical and pharmaceutical markets in collaboration with global international partners. The
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes 2Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 2Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 3Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 4Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 5Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 6Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 7Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 8Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 9Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4